Return to Today's science sparks archives

2011-01-03

Fig 1. Significant group differences were found for the FACT-Cx scale, in which the radical trachelectomy patients had a significantly more gradual linear improvement as well as a significantly less-prounounced arc in their trajectory compared to the radical hysterectomy patients.

Fig 1. Significant group differences were found for the FACT-Cx scale, in which the radical trachelectomy patients had a significantly more gradual linear improvement as well as a significantly less-prounounced arc in their trajectory compared to the radical hysterectomy patients.
  • Carter J, Sonoda Y, Baser RE, Raviv L, Chi DS, Barakat RR, Iasonos A, Brown CL, Abu-Rustum NR

  • Gynecol Oncol. 2010 Nov;119(2):358-65.

2011-01-04

Fig 1b. Chest radiograph of a patient after fracture of the mediport catheter from the subcutaneous reservoir. The catheter tubing has migrated to the right ventricle.

Fig 1b. Chest radiograph of a patient after fracture of the mediport catheter from the subcutaneous reservoir. The catheter tubing has migrated to the right ventricle.
  • Kayton ML, Garmey EG, Ishill NM, Cheung NK, Kushner BH, Kramer K, Modak S, Rossetto C, Hennelly C, Doyle MP, Rosenberg S, Santoro O, La Quaglia MP

  • J Pediatr Surg. 2010 Oct;45(10):1961-6.

2011-01-05

Fig 3.Immunoblotting for Parc and p53. a, control (untreated) cells showing abundant p53 and Parc; b, Parc knockdown after Parc siRNA interference, showing presence of a light Parc band confirming knockdown, but the p53 band still persists.

Fig 3.Immunoblotting for Parc and p53. a, control (untreated) cells showing abundant p53 and Parc; b, Parc knockdown after Parc siRNA interference, showing presence of a light Parc band confirming knockdown, but the p53 band still persists.
  • Mulhall JP, Barnas J, Kobylarz K, Mueller A

  • BJU Int. 2010 Dec;106(11):1706-13.

2011-01-06

Fig 2. Inhibition curves for deazaTh and deazaThDP.

Fig 2. Inhibition curves for deazaTh and deazaThDP.
  • Zhao H, de Carvalho LP, Nathan C, Ouerfelli O

  • Bioorg Med Chem Lett. 2010 Nov 15;20(22):6472-4.

2011-01-07

Fig 2. Enhanced osteoclast differentiation in Id1-/- mice.

Fig 2. Enhanced osteoclast differentiation in Id1-/- mice.
  • Chan AS, Jensen KK, Skokos D, Doty S, Lederman HK, Kaplan RN, Rafii S, Rivella S, Lyden D

  • PLoS One. 2009 Nov 24;4(11):e7955.
Open Access button

2011-01-10

Fig 2. An esophagogastroduodenoscopy was performed, which revealed a PillCam SB (Given Imaging, Ltd) in the gastric body.

Fig 2. An esophagogastroduodenoscopy was performed, which revealed a PillCam SB (Given Imaging, Ltd) in the gastric body.
  • Ihekweazu UN, Ludwig E, Flores RM

  • Ann Thorac Surg. 2010 Aug;90(2):673.

2011-01-11

Fig 3. Antitumor Response in Each of the 32 Patients in the Extension Cohort.

Fig 3. Antitumor Response in Each of the 32 Patients in the Extension Cohort.
  • Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB

  • N Engl J Med. 2010 Aug 26;363(9):809-19.

2011-01-12

Fig 8b. Evidence for transcriptional interference. The RNA signals (average of each replicate) for strains relevant to the transcriptional interference locus are displayed as line graphs.

Fig 8b. Evidence for transcriptional interference. The RNA signals (average of each replicate) for strains relevant to the transcriptional interference locus are displayed as line graphs.
  • Yadon AN, Van de Mark D, Basom R, Delrow J, Whitehouse I, Tsukiyama T

  • Mol Cell Biol. 2010 Nov;30(21):5110-22.

2011-01-13

A sequence consisting of a Lewis acid-catalyzed Diels−Alder reaction on a 2-halocyclohexenone, followed by reductive alkylation, provides a route to trans-fused octalinones bearing angular methyl groups with functionality corresponding to that which would have been possible from a trans-directed Diels−Alder reaction.

A sequence consisting of a Lewis acid-catalyzed Diels−Alder reaction on a 2-halocyclohexenone, followed by reductive alkylation, provides a route to trans-fused octalinones bearing angular methyl groups with functionality corresponding to that which would have been possible from a trans-directed Diels−Alder reaction.
  • Lee JH, Zhang Y, Danishefsky SJ

  • J Am Chem Soc. 2010 Oct 20;132(41):14330-3.

2011-01-14

This article reviews features of phase 2 trials in AML that may contribute to the high frequency of false-positive results, particularly lack of control groups, patient heterogeneity, selection bias, and choice of end points.

This article reviews features of phase 2 trials in AML that may contribute to the high frequency of false-positive results, particularly lack of control groups, patient heterogeneity, selection bias, and choice of end points.
  • Walter RB, Appelbaum FR, Tallman MS, Weiss NS, Larson RA, Estey EH

  • Blood. 2010 Oct 7;116(14):2420-8.

2011-01-17

Fig 4. Molecular control of TGF-beta-induced Treg cell differentiation.

Fig 4. Molecular control of TGF-beta-induced Treg cell differentiation.
  • Ouyang W, Li MO

  • Trends Immunol. 2011 Jan;32(1):26-33.

2011-01-18

Fig 1. Bleomycin-induced pulmonary toxicity. Patient undergoing treatment for lymphoma presented with new-onset dyspnea and decrease in diffusing capacity 5 months after initiation of treatment.

Fig 1. Bleomycin-induced pulmonary toxicity. Patient undergoing treatment for lymphoma presented with new-onset dyspnea and decrease in diffusing capacity 5 months after initiation of treatment.
  • Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H

  • Radiology. 2011 Jan;258(1):41-56.

2011-01-19

Fig 3B). Corresponding RCM and histological images of a superficial BCC. Corresponding histological section showing tumor nodules surrounded by mucin (black arrowheads).

Fig 3B). Corresponding RCM and histological images of a superficial BCC. Corresponding histological section showing tumor nodules surrounded by mucin (black arrowheads).
  • Ulrich M, Roewert-Huber J, González S, Rius-Diaz F, Stockfleth E, Kanitakis J

  • J Cutan Pathol. 2011 Feb;38(2):190-5.

2011-01-20

Fig 5a. Venn-diagram of genes differentially expressed in prospectively isolated CWR22 OT-tumour cells with low (expressing EpCAM, CD44 or α2-integrin), moderate (expressing TRA-1-60, CD151 or CD166) and high (triple-marker-positives) sphere/tumour-forming efficiencies (S/TFE).

Fig 5a. Venn-diagram of genes differentially expressed in prospectively isolated CWR22 OT-tumour cells with low (expressing EpCAM, CD44 or α2-integrin), moderate (expressing TRA-1-60, CD151 or CD166) and high (triple-marker-positives) sphere/tumour-forming efficiencies (S/TFE).
  • Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI

  • Nat Commun. 2011 Jan;2(1):162.

2011-01-21

TMLI isodose distribution shows the colorwash isodose distribution of a patient receiving 12 Gy TMLI.

TMLI isodose distribution shows the colorwash isodose distribution of a patient receiving 12 Gy TMLI.
  • Giralt S

  • Blood. 2011 Jan 6;117(1):9.

2011-01-24

Fig 1. Schematic representation of the mathematical model.

Fig 1. Schematic representation of the mathematical model.
  • Leder K, Holland EC, Michor F

  • PLoS One. 2010 Dec 17;5(12):e14366.
Open Access button

2011-01-25

Fig 3. Model for pathways involved in chromosomal translocations.

Fig 3. Model for pathways involved in chromosomal translocations.
  • Zhang Y, Jasin M

  • Nat Struct Mol Biol. 2011 Jan;18(1):80-4.

2011-01-26

Fig 1. Schematic representation of estimated disease extension at diagnosis of retinoblastoma in three different countries.

Fig 1. Schematic representation of estimated disease extension at diagnosis of retinoblastoma in three different countries.
  • Chantada GL, Qaddoumi I, Canturk S, Khetan V, Ma Z, Kimani K, Yeniad B, Sultan I, Sitorus RS, Tacyildiz N, Abramson DH

  • Pediatr Blood Cancer. 2011 Mar;56(3):341-8.

2011-01-27

Fig 1. PFS by adjuvant chemotherapy, yes/no (for stage II/III/IV and serous patients).

Fig 1. PFS by adjuvant chemotherapy, yes/no (for stage II/III/IV and serous patients).
  • Shih KK, Zhou QC, Aghajanian C, Huh J, Soslow RA, Morgan JC, Iasonos A, Chi DS, Barakat RR, Abu-Rustum NR

  • Gynecol Oncol. 2010 Nov;119(2):270-3.

2011-01-28

Fig 5. CCDC40 mutations affect localization of CCDC39 in respiratory cells.

Fig 5. CCDC40 mutations affect localization of CCDC39 in respiratory cells.
  • Becker-Heck A, Zohn IE, Okabe N, Pollock A, Lenhart KB, Sullivan-Brown J, McSheene J, Loges NT, Olbrich H, Haeffner K, Fliegauf M, Horvath J, Reinhardt R, Nielsen KG, Marthin JK, Baktai G, Anderson KV, Geisler R, Niswander L, Omran H, Burdine RD

  • Nat Genet. 2011 Jan;43(1):79-84.

2011-01-31

Fig 1.(B) Summary of SDHB IHC scores in pediatric (n = 14) and adult (n = 12) WT GIST, KIT mutant GIST (n = 15), and NF-1–associated GIST (n = 5).

Fig 1.(B) Summary of SDHB IHC scores in pediatric (n = 14) and adult (n = 12) WT GIST, KIT mutant GIST (n = 15), and NF-1–associated GIST (n = 5).
  • Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, Gaal J, Dahia PL, Liegl B, Ball ER, Raygada M, Lai AH, Kelly L, Hornick JL; NIH Pediatric and Wild-Type GIST Clinic, O'Sullivan M, de Krijger RR, Dinjens WN, Demetri GD, Antonescu CR, Fletcher JA, Helman L, Stratakis CA

  • Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):314-8.

2011-02-01

Fig 2. Cumulative Incidence Functions for Utilization of Mammography Screenings Following Advanced Cancer Diagnosis by Cancer Site.

Fig 2. Cumulative Incidence Functions for Utilization of Mammography Screenings Following Advanced Cancer Diagnosis by Cancer Site.
  • Sima CS, Panageas KS, Schrag D

  • JAMA. 2010 Oct 13;304(14):1584-91.

2011-02-02

Fig 6. mtDNA-encoded protein deformylation occurs in the mitochondria.

Fig 6. mtDNA-encoded protein deformylation occurs in the mitochondria.
  • Escobar-Alvarez S, Gardner J, Sheth A, Manfredi G, Yang G, Ouerfelli O, Heaney ML, Scheinberg DA

  • Mol Cell Biol. 2010 Nov;30(21):5099-109.

2011-02-03

Fig 2a. Genomic DNA from bone marrow mononuclear cells at complete histologic remission from follicular lymphoma (2002).

Fig 2a. Genomic DNA from bone marrow mononuclear cells at complete histologic remission from follicular lymphoma (2002).
Highly cited
  • Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S

  • Cancer Res. 2010 Jan 15;70(2):447-52.

2011-02-04

Fig 1b. Sagittal view of PET scan after 4 weeks of treatment.

Fig 1b. Sagittal view of PET scan after 4 weeks of treatment.
Highly cited
  • Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium

  • Lancet. 2010 Apr 24;375(9724):1437-46.

2011-02-07

Fig 2i. Tumors were dissected and fresh frozen in optimum cutting temperature solution, cut, and stained for DAPI (blue), CD31 (red), and CD4 (green).

Fig 2i. Tumors were dissected and fresh frozen in optimum cutting temperature solution, cut, and stained for DAPI (blue), CD31 (red), and CD4 (green).
Highly cited
  • Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP

  • J Exp Med. 2010 Mar 15;207(3):637-50.

2011-02-08

Fig 3. Integration of Environmental Cues by Proinflammatory Effector T Cells and Anti-inflammatory Treg Cells in the GutCytokine microenvironment impacted by the gut microbiota promotes Stat3 phosphorylation, which in turn induces differentiation of activated T cells into Th17 effector cells.

Fig 3. Integration of Environmental Cues by Proinflammatory Effector T Cells and Anti-inflammatory Treg Cells in the GutCytokine microenvironment impacted by the gut microbiota promotes Stat3 phosphorylation, which in turn induces differentiation of activated T cells into Th17 effector cells.
Highly cited
  • Littman DR, Rudensky AY

  • Cell. 2010 Mar 19;140(6):845-58.

2011-02-09

Fig 4c. Bright-field imaging and haematoxylin/eosin staining (H&E) of lungs isolated from mice that received an orthotopic injection of 4T1 cells infected with the miR-9 sponge or control sponge, at 4 weeks after transplantation.

Fig 4c. Bright-field imaging and haematoxylin/eosin staining (H&E) of lungs isolated from mice that received an orthotopic injection of 4T1 cells infected with the miR-9 sponge or control sponge, at 4 weeks after transplantation.
Highly cited
  • Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA

  • Nat Cell Biol. 2010 Mar;12(3):247-56.

2011-02-10

Fig 1a. HeLa S3 cells were SILAC-labeled with three different isotopic forms of arginine and lysine.

Fig 1a. HeLa S3 cells were SILAC-labeled with three different isotopic forms of arginine and lysine.
Highly cited
  • Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, Gnad F, Cox J, Jensen TS, Nigg EA, Brunak S, Mann M

  • Sci Signal. 2010 Jan 12;3(104):ra3.

2011-02-11

Fig 1. This is a graphic representation of the adenoma-carcinoma sequence in the microsimulation screening analysis (MISCAN-Colon) model and potential interventions that affect the natural history of disease.

Fig 1. This is a graphic representation of the adenoma-carcinoma sequence in the microsimulation screening analysis (MISCAN-Colon) model and potential interventions that affect the natural history of disease.
Highly cited
  • Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA

  • Cancer. 2010 Feb 1;116(3):544-73.

2011-02-14

Fig 1h. Binding of NF-κB family member c-Rel but not p65 to the CD28RE-like element at CNS3.

Fig 1h. Binding of NF-κB family member c-Rel but not p65 to the CD28RE-like element at CNS3.
Highly cited
  • Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY

  • Nature. 2010 Feb 11;463(7282):808-12.

2011-02-15

Fig 1. Representative histopathologic changes associated with fatal pandemic influenza A/H1N1 infection.

Fig 1. Representative histopathologic changes associated with fatal pandemic influenza A/H1N1 infection.
Highly cited
  • Gill JR, Sheng ZM, Ely SF, Guinee DG, Beasley MB, Suh J, Deshpande C, Mollura DJ, Morens DM, Bray M, Travis WD, Taubenberger JK

  • Arch Pathol Lab Med. 2010 Feb;134(2):235-43.

2011-02-16

Fig 3b. Antitumor Response in Each of the 32 Patients in the Extension Cohort.

Fig 3b. Antitumor Response in Each of the 32 Patients in the Extension Cohort.
Highly cited
  • Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB

  • N Engl J Med. 2010 Aug 26;363(9):809-19.

2011-02-17

Fig 6. Risks of a disease-free survival event by linear recurrence score, treatment, and number of positive nodes, for 10-year timepoints.

Fig 6. Risks of a disease-free survival event by linear recurrence score, treatment, and number of positive nodes, for 10-year timepoints.
Highly cited
  • Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Breast Cancer Intergroup of North America

  • Lancet Oncol. 2010 Jan;11(1):55-65.

2011-02-18

Fig 1. IDH1 R132 and IDH2 R172 Are Analogous Residues that Both Interact with the beta-Carboxyl of Isocitrate.

Fig 1. IDH1 R132 and IDH2 R172 Are Analogous Residues that Both Interact with the beta-Carboxyl of Isocitrate.
Highly cited
  • Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB

  • Cancer Cell. 2010 Mar 16;17(3):225-34.

2011-02-21

Supp Fig 1b. Model of the effects of RAF inhibitors in the presence of wild-type BRAF.

Supp Fig 1b. Model of the effects of RAF inhibitors in the presence of wild-type BRAF.
Highly cited
  • Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N

  • Nature. 2010 Mar 18;464(7287):427-30.

2011-02-22

Fig 4. Single sample GSEA scores of GBM subtypes show a relation to specific cell types.

Fig 4. Single sample GSEA scores of GBM subtypes show a relation to specific cell types.
Highly cited
  • Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network

  • Cancer Cell. 2010 Jan 19;17(1):98-110.

2011-02-23

Fig 1a. Kaplan–Meier Curves for Overall Survival and Progression-free Survival in the Intention-to-Treat Population.

Fig 1a. Kaplan–Meier Curves for Overall Survival and Progression-free Survival in the Intention-to-Treat Population.
Highly cited
  • Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ

  • N Engl J Med. 2010 Aug 19;363(8):711-23.

2011-02-24

The WHO Nomenclature Committee for Factors of the HLA System met following the 14th International HLA and Immunogenetics Workshop in Melbourne, Australia in December 2005 and Buzios, Brazil during the 15th International HLA and Immunogenetics Workshop in September 2008. This report documents the additions and revisions to the nomenclature of HLA specificities following the principles established in previous reports.

The WHO Nomenclature Committee for Factors of the HLA System met following the 14th International HLA and Immunogenetics Workshop in Melbourne, Australia in December 2005 and Buzios, Brazil during the 15th International HLA and Immunogenetics Workshop in September 2008. This report documents the additions and revisions to the nomenclature of HLA specificities following the principles established in previous reports.
Highly cited
  • Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Fernández-Viña M, Geraghty DE, Holdsworth R, Hurley CK, Lau M, Lee KW, Mach B, Maiers M, Mayr WR, Müller CR, Parham P, Petersdorf EW, Sasazuki T, Strominger JL, Svejgaard A, Terasaki PI, Tiercy JM, Trowsdale J

  • Tissue Antigens. 2010 Apr;75(4):291-455.

2011-02-24

Fig 1. Risk of MPM on head and neck and other body sites.

Fig 1. Risk of MPM on head and neck and other body sites.
  • Kricker A, Armstrong BK, Goumas C, Kanetsky P, Gallagher RP, Begg CB, Millikan RC, Dwyer T, Rosso S, Marrett LD, Thomas NE, Berwick M; GEM Study Group

  • Cancer Causes Control. 2010 Dec;21(12):2137-47.

2011-02-25

Fig 2b. Average gene density as a function of copy number.

Fig 2b. Average gene density as a function of copy number.
Highly cited
  • Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M

  • Nature. 2010 Feb 18;463(7283):899-905.

2011-02-28

Fig 5a. Surface Representation of Combined Effect of Dosage and Antigen Density on Therapeutic Ratio.

Fig 5a. Surface Representation of Combined Effect of Dosage and Antigen Density on Therapeutic Ratio.
  • He P, Kramer K, Smith-Jones P, Zanzonico P, Humm J, Larson SM, Cheung NK

  • Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):334-42.

2011-03-01

Fig 1. Treatment algorithm for the oncology team and/or
general gynecologist for vaginal health promotion in female
cancer survivors.

Fig 1. Treatment algorithm for the oncology team and/or general gynecologist for vaginal health promotion in female cancer survivors.
  • Carter J, Goldfrank D, Schover LR

  • J Sex Med. 2011 Feb;8(2):549-59.

2011-03-02

Fig 1. Visualization of the protein embedding.

Fig 1. Visualization of the protein embedding.
  • Melvin I, Weston J, Noble WS, Leslie C

  • PLoS Comput Biol. 2011 Jan 27;7(1):e1001047.
Open Access button

2011-03-03

Fig 2a. The amino acid sequence of EcoPrrC is aligned to sequences of the NmePrrC, SmuPrrC, and XcaPrrC proteins. Positions of side-chain identify/similarity in all four proteins are indicated by a filled black circle above the alignment. The conserved peptide motifs of the N-terminal NTPase domain are demarcated by brackets. The 54 amino acids targeted in the alanine scan are highlighted.

Fig 2a. The amino acid sequence of EcoPrrC is aligned to sequences of the NmePrrC, SmuPrrC, and XcaPrrC proteins. Positions of side-chain identify/similarity in all four proteins are indicated by a filled black circle above the alignment. The conserved peptide motifs of the N-terminal NTPase domain are demarcated by brackets. The 54 amino acids targeted in the alanine scan are highlighted.
  • Meineke B, Schwer B, Schaffrath R, Shuman S

  • Nucleic Acids Res. 2011 Jan;39(2):687-700.

2011-03-04

Fig 1. Primary diffuse large B-cell lymphoma of the CNS in a 12-year-old patient.

Fig 1. Primary diffuse large B-cell lymphoma of the CNS in a 12-year-old patient.
  • Abla O, Weitzman S, Blay JY, O'Neill BP, Abrey LE, Neuwelt E, Doolittle ND, Baehring J, Pradhan K, Martin SE, Guerrera M, Shah S, Ghesquieres H, Silver M, Betensky RA, Batchelor T

  • Clin Cancer Res. 2011 Jan 15;17(2):346-52.

2011-03-07

Fig 7. Model for Swi6 regulation of centromere replication.

Fig 7. Model for Swi6 regulation of centromere replication.
  • Li PC, Chretien L, Côté J, Kelly TJ, Forsburg SL

  • Cell Cycle. 2011 Jan 15;10(2):323-36.
Open Access button

2011-03-08

Fig 3. The first PET/CT (A) shows only mild 18F-FDG uptake in the thoracic aorta wall (arrows). In a repeat examination (B), performed 70 days later, the vascular uptake is much more intense (arrows) and sites of 18F-FDG accumulation are also seen in brown fat tissue.

Fig 3. The first PET/CT (A) shows only mild 18F-FDG uptake in the thoracic aorta wall (arrows). In a repeat examination (B), performed 70 days later, the vascular uptake is much more intense (arrows) and sites of 18F-FDG accumulation are also seen in brown fat tissue.
  • Meirelles GS, Gonen M, Strauss HW

  • J Thorac Imaging. 2011 Feb;26(1):54-62.

2011-03-09

Fig 6ab. Correlation of transcript expression with the pattern of intragenic methylation in M091 cells.

Fig 6ab. Correlation of transcript expression with the pattern of intragenic methylation in M091 cells.
  • Brenet F, Moh M, Funk P, Feierstein E, Viale AJ, Socci ND, Scandura JM

  • PLoS One. 2011 Jan 18;6(1):e14524.
Open Access button

2011-03-10

Fig 6b. Jurkat T cells were transiently-transfected as in A, with the exception that cells were additionally cotransfected with a plasmid encoding CXCR4-WT-YFP (green).

Fig 6b. Jurkat T cells were transiently-transfected as in A, with the exception that cells were additionally cotransfected with a plasmid encoding CXCR4-WT-YFP (green).
  • Kumar A, Kremer KN, Dominguez D, Tadi M, Hedin KE

  • J Immunol. 2011 Jan 15;186(2):951-8.

2011-03-11

Fig 2. Three-year recurrence-free survival of 126 patients followed by NBI cystoscopy; 78 patients had tumour recurrence; median (95% CI) recurrence-free survival time was 29 (26–32) months.

Fig 2. Three-year recurrence-free survival of 126 patients followed by NBI cystoscopy; 78 patients had tumour recurrence; median (95% CI) recurrence-free survival time was 29 (26–32) months.
  • Herr HW, Donat SM

  • BJU Int. 2011 Feb;107(3):396-8.

2011-03-14

Fig 2. Adenocarcinoma infiltrating among lower uterine segment glands (top right) and mucinous glands (center). Some observers considered this to represent endocervical involvement by tumor whereas other observers did not.

Fig 2. Adenocarcinoma infiltrating among lower uterine segment glands (top right) and mucinous glands (center). Some observers considered this to represent endocervical involvement by tumor whereas other observers did not.
  • McCluggage WG, Hirschowitz L, Wilson GE, Oliva E, Soslow RA, Zaino RJ

  • Am J Surg Pathol. 2011 Feb;35(2):289-94.

2011-03-15

Fig 1. Probability of local recurrence in patients with recurrent or persistent neuroblastoma after re-resection and IORT.

Fig 1. Probability of local recurrence in patients with recurrent or persistent neuroblastoma after re-resection and IORT.
  • Rich BS, McEvoy MP, LaQuaglia MP, Wolden SL

  • J Pediatr Surg. 2011 Jan;46(1):97-102.

2011-03-16

Fig 1. Suspicious right chest wall mass.

Fig 1. Suspicious right chest wall mass.
  • González SJ, González L, Wong J, Brader P, Zakowski M, Gönen M, Daghighian F, Fong Y, Strong VE

  • J Gastrointest Surg. 2011 Feb;15(2):358-66.

2011-03-17

Fig 1. Tumor heterogeneity: crosstalk between tumor cells and nontumor cells.

Fig 1. Tumor heterogeneity: crosstalk between tumor cells and nontumor cells.
  • Sansone P, Bromberg J

  • Current Opinion in Genetics and Development. 2011 Feb; 21(1):80-85.

2011-03-18

Fig S8. Working Model for RNA Exosome-Dependent AID Activity on Transcribed Duplex DNA Substrates.

Fig S8. Working Model for RNA Exosome-Dependent AID Activity on Transcribed Duplex DNA Substrates.
  • Basu U, Meng FL, Keim C, Grinstein V, Pefanis E, Eccleston J, Zhang T, Myers D, Wasserman CR, Wesemann DR, Januszyk K, Gregory RI, Deng H, Lima CD, Alt FW

  • Cell. 2011 Feb 4;144(3):353-63.

2011-03-21

Fig 2. Comparison of CD8+ T cell and NK cell differentiation and memory generation following viral infection.

Fig 2. Comparison of CD8+ T cell and NK cell differentiation and memory generation following viral infection.
  • Sun JC, Lopez-Verges S, Kim CC, DeRisi JL, Lanier LL

  • J Immunol. 2011 Feb 15;186(4):1891-7.

2011-03-22

Fig 5. Anti-CD47 antibody eliminates ALL engraftment in the PB and BM. (D)BM sections from hematoxylin and eosin (H&E) staining (top) and immunohistochemical human CD45 staining (bottom) are shown from representative mice engrafted with B-ALL posttreatment.

Fig 5. Anti-CD47 antibody eliminates ALL engraftment in the PB and BM. (D)BM sections from hematoxylin and eosin (H&E) staining (top) and immunohistochemical human CD45 staining (bottom) are shown from representative mice engrafted with B-ALL posttreatment.
  • Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R

  • Cancer Res. 2011 Feb 15;71(4):1374-84.

2011-03-23

Fig 4. SOX7 and SOX17 are detected in PrE derivatives at E5.5 postimplantation stage.

Fig 4. SOX7 and SOX17 are detected in PrE derivatives at E5.5 postimplantation stage.
  • Artus J, Piliszek A, Hadjantonakis AK

  • Dev Biol. 2011 Feb 15;350(2):393-404.

2011-03-24

Fig 4. MiTF/TFE family translocation-associated carcinoma.

Fig 4. MiTF/TFE family translocation-associated carcinoma.
  • Tickoo SK, Reuter VE

  • Adv Anat Pathol. 2011 Mar;18(2):120-31.

2011-03-25

Fig 2. MDS plots of pre-TBI samples using the ex vivo gene signature.

Fig 2. MDS plots of pre-TBI samples using the ex vivo gene signature.
  • Paul S, Barker CA, Turner HC, McLane A, Wolden SL, Amundson SA

  • Radiat Res. 2011 Mar;175(3):257-65.

2011-03-28

Fig 6. Recipient-derived macrophages express the lymphatic endothelial cell marker LYVE-1 after tissue transfer.

Fig 6. Recipient-derived macrophages express the lymphatic endothelial cell marker LYVE-1 after tissue transfer.
  • Yan A, Avraham T, Zampell JC, Aschen SZ, Mehrara BJ

  • PLoS One. 2011 Feb 17;6(2):e17201.
Open Access button

2011-03-29

Fig 2b. PAR-3 and its inhibitors in the C. elegans zygote and early embryo.

Fig 2b. PAR-3 and its inhibitors in the C. elegans zygote and early embryo.
  • Nance J, Zallen JA

  • Development. 2011 Mar;138(5):799-809.

2011-03-30

Fig 2a. The MRE11 complex consists of a globular domain and extended coiled-coils.

Fig 2a. The MRE11 complex consists of a globular domain and extended coiled-coils.
  • Stracker TH, Petrini JH

  • Nat Rev Mol Cell Biol. 2011 Feb;12(2):90-103.

2011-03-31

Fig 1. CALGB trial 79809 schema.

Fig 1. CALGB trial 79809 schema.
  • Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E

  • Eur J Cancer. 2011 Mar;47(5):683-9.

2011-04-01

Fig 1a. Late PAR pairing during male meiosis.

Fig 1a. Late PAR pairing during male meiosis.
  • Kauppi L, Barchi M, Baudat F, Romanienko PJ, Keeney S, Jasin M

  • Science. 2011 Feb 18;331(6019):916-20.